M&T Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

M&T Bank’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,544	Closed	-$452K	–	1614
2018 Q2	$452K	Sell	7,544 -1,609	-18%	-$83.4K	﹤0.01%	1050
2018 Q1	$419K	Sell	9,153 -1,415	-13%	-$59K	﹤0.01%	1079
2017 Q4	$422K	Buy	10,568 +3,931	+59%	+$155K	﹤0.01%	1081
2017 Q3	$266K	Buy	6,637 +1,683	+34%	+$72.8K	﹤0.01%	1289
2017 Q2	$213K	Buy	+4,954	New	+$176K	﹤0.01%	1388

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

M&T Bank's SUPN Position: Q3 2018 in Review

M&T Bank sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 7,544 shares — an estimated $452K sold.

M&T Bank first reported a position in SUPN in Q2 2017 and held it in 5 quarters. The position peaked at $452K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

M&T Bank reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
M&T Bank sold 7,544 Supernus Pharmaceuticals shares in Q3 2018, an estimated $452K.
M&T Bank first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 5 quarters.
M&T Bank's Supernus Pharmaceuticals position peaked at $452K in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on M&T Bank's 13F filing for Q3 2018, filed 9 Nov 2018.